Atopic dermatitis (AD), commonly known as eczema, affects over 230 million people worldwide and is the most prevalent chronic inflammatory skin disease. It is characterized by intense pruritus, eczematous lesions, and a relapsing-remitting course that profoundly impacts quality of life — sleep disturbance, social embarrassment, and lost productivity are near-universal features. AD is driven by a complex interplay of epidermal barrier dysfunction (often involving FLG gene mutations), type-2-skewed immune dysregulation, and IgE-mediated allergic sensitization, creating a self-amplifying inflammatory loop that resists simple intervention [1].

Where conventional therapies fall short. Moisturizers, topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunosuppressants (cyclosporine, methotrexate) form the standard treatment ladder. Newer biologics (dupilumab, targeting IL-4Rα) and JAK inhibitors (upadacitinib, abrocitinib) have improved outcomes, but all require ongoing administration, carry risks of infection and laboratory monitoring burdens, and lose efficacy in a subset of patients. More fundamentally, they suppress downstream mediators rather than restoring the broader immune homeostasis whose breakdown sustains the disease [2].

The deeper problem is immunological, not dermatological. In AD, keratinocyte-derived TSLP (thymic stromal lymphopoietin) and IL-33 activate type-2 innate lymphoid cells (ILC2s) and dendritic cells, which polarize naïve T cells toward a Th2 phenotype. Th2 cells produce IL-4, IL-5, and IL-13 — cytokines that drive IgE class-switching, eosinophil recruitment, and further barrier disruption via filaggrin downregulation. This creates a vicious cycle: barrier damage triggers inflammation, which further damages the barrier. The chronic phase additionally recruits Th22 and Th1/Th17 pathways, explaining why AD resists single-cytokine blockade in many patients [3].

MSC therapy targets the upstream immune dysregulation. Rather than blocking one cytokine, mesenchymal stem cells exert broad immunomodulatory effects addressing multiple nodes in the atopic cascade simultaneously — suppressing dendritic cell maturation, shifting the Th2/Treg balance toward regulation, inhibiting mast cell degranulation, and secreting factors that directly strengthen the epidermal barrier [4]. This multi-target, network-level mechanism distinguishes MSC therapy from single-pathway biologics and makes it a compelling investigational approach for a disease driven by systemic immune dysfunction.

How MSCs Target the Pathophysiology of Atopic Dermatitis

MSCs address atopic dermatitis through four interconnected mechanisms, each targeting a different node in the inflammatory cascade [5].

Th2-to-Treg rebalancing. The hallmark of AD is a dominant Th2 response producing IL-4, IL-5, and IL-13. MSCs secrete prostaglandin E2 (PGE2), TGF-β, and IL-10, which suppress Th2 differentiation while promoting regulatory T cell (Treg) expansion. In a mouse model of oxazolone-induced AD-like dermatitis, intravenous MSC administration reduced IL-4 and IL-13 levels by 55–70% while increasing FoxP3+ Tregs in lesional skin and draining lymph nodes [6]. The resulting shift from a Th2-dominant to a Treg-dominant milieu is arguably more disease-modifying than blocking any single downstream cytokine.

Dendritic cell modulation and TSLP suppression. TSLP is the master initiator of the atopic cascade — released by damaged keratinocytes, it activates dendritic cells to drive Th2 polarization. MSCs suppress TSLP production by keratinocytes via paracrine factors including TSG-6 (TNF-α-stimulated gene 6). In vitro, MSC-conditioned medium reduced TSLP secretion from IL-4/TNF-α-stimulated human keratinocytes by approximately 60%, effectively intercepting the cascade at its most upstream point [7].

Mast cell stabilization. Mast cells are central to the intense pruritus (itch) that defines AD. IgE bound to high-affinity FcεRI receptors on mast cells triggers degranulation and histamine release upon allergen encounter. MSCs inhibit mast cell degranulation through PGE2-mediated signaling via the EP4 receptor — a mechanism demonstrated in passive cutaneous anaphylaxis models showing >50% reduction in mast cell-dependent vascular leakage after MSC administration [8].

Epidermal barrier restoration. Beyond immunomodulation, MSCs promote structural repair. MSC-derived exosomes carry growth factors (EGF, HGF, VEGF) and microRNAs that stimulate keratinocyte proliferation and migration, accelerate wound closure, and upregulate filaggrin and loricrin expression — key structural proteins of the epidermal barrier. In a murine tape-stripping model of barrier disruption, topical MSC exosomes accelerated barrier recovery by 40% compared to vehicle control [9].

Preclinical Evidence: What Animal Models Show

The preclinical case for MSCs in AD rests on consistent findings across multiple independent laboratories and model systems.

Oxazolone and DNCB models. In hapten-induced AD-like dermatitis models (oxazolone and DNCB), intravenous or subcutaneous MSC administration produced consistent effects: reduced clinical severity scores (30–50% improvement by day 14), decreased epidermal thickness on histology, lower serum IgE levels, and reduced infiltration of mast cells, eosinophils, and CD4+ T cells into lesional skin. Shin et al. (2017) demonstrated that human umbilical cord blood-derived MSCs suppressed AD in NC/Nga mice — a spontaneous model closely mimicking human AD — reducing dermatitis scores from severe to mild while normalizing serum IgE [10].

Mechanism validation. Multiple studies have confirmed the mechanism through depletion experiments: the therapeutic effect was abolished when MSCs were pre-treated with indomethacin (a COX-2/PGE2 inhibitor), confirming PGE2 as the key mediator. Similarly, TSG-6 knockdown MSCs lost their ability to suppress TSLP. These loss-of-function experiments provide strong mechanistic evidence that the observed benefits are MSC-specific and paracrine-mediated, not artifacts of the model system [11].

Topical vs. systemic delivery. Both intravenous and topical MSC delivery have shown efficacy in animal models, but with important differences. Intravenous administration achieves systemic immunomodulation and reduces circulating IgE, while topical application (MSC-conditioned medium or exosomes) primarily enhances local barrier repair. A 2020 study comparing routes found that combined IV + topical administration yielded superior outcomes to either route alone in a mouse model, suggesting complementary mechanisms [12].

Clinical Evidence: Early Human Studies

Human data on MSC therapy for atopic dermatitis remains limited but is growing. The evidence base includes case reports, small open-label trials, and one randomized controlled study.

Case reports and series. Kim et al. (2016) reported a case of severe, treatment-resistant AD in a 32-year-old woman who received two intravenous infusions of allogeneic umbilical cord blood-derived MSCs (1 × 10⁶ cells/kg). At 16-week follow-up, her EASI (Eczema Area and Severity Index) score had decreased from 48.7 to 12.3, serum IgE had dropped by 55%, and she reported sustained cessation of systemic immunosuppressants. Lee et al. (2019) described a series of five adult AD patients treated with intravenous allogeneic MSCs, all of whom achieved EASI-50 (≥50% improvement) at 12 weeks, with three maintaining EASI-75 at 24 weeks [13].

Open-label trial. A 2021 prospective open-label study enrolled 20 adults with moderate-to-severe AD (baseline EASI ≥ 16) who received three monthly intravenous infusions of Wharton's jelly-derived MSCs (2 × 10⁶ cells/kg). At 6-month follow-up, mean EASI decreased from 24.8 to 11.2 (p < 0.01), DLQI (Dermatology Life Quality Index) improved from 18.4 to 8.7, and daily topical corticosteroid use decreased by 62%. No serious adverse events were reported; mild infusion-related fever occurred in three patients and resolved spontaneously [14].

Pediatric data. A small Chinese study (2022) treated eight children aged 3–12 years with severe, multi-drug-resistant AD using three intravenous umbilical cord MSC infusions. At 6 months, seven of eight achieved EASI-50; four achieved EASI-75. Pruritus scores (visual analog scale) improved from a mean of 8.2/10 to 3.1/10. The key limitation is sample size — these are exploratory data, not confirmatory evidence [15].

Comparison with Existing Therapies

How does MSC therapy conceptually compare with the current standard of care? This is not a clinical efficacy comparison — no head-to-head trials exist — but rather a mechanistic perspective on how these approaches differ.

FeatureTopicals/PhototherapyBiologics (Dupilumab)JAK InhibitorsMSC Therapy
TargetSymptom suppressionIL-4Rα (Th2)JAK-STAT (broad)Multi-node immunomodulation
AdministrationDailyEvery 2 weeks injectionDaily oralIV infusion (periodic)
Barrier repairIndirectIndirectIndirectDirect (growth factors)
Systemic immune resetNoPartialPartialYes (Treg expansion)
Mast cell/IgE effectNoIndirectNoYes (mast cell stabilization)
DurabilityDaysWeeks (requires ongoing)DaysMonths (under investigation)
StatusApprovedApprovedApprovedInvestigational

What distinguishes the MSC approach is its breadth: rather than interrupting one signaling pathway, MSCs engage the entire immunological network — calming dendritic cells, rebalancing T-cell subsets, stabilizing mast cells, and directly repairing barrier damage. This polypharmacology is both the appeal and the challenge: it makes predicting individual patient responses difficult with current biomarkers [16].

Limitations and Honest Assessment

This is where the evidence must be weighed honestly. MSC therapy for atopic dermatitis is investigational — not established standard of care — and several critical questions remain unanswered.

No large-scale randomized trials. The strongest human evidence is the 20-patient open-label study; there is no multi-center, randomized, placebo-controlled trial. Without randomization and blinding, placebo effects (significant in AD trials, where vehicle-controlled topical studies show 20–30% placebo responses) and spontaneous fluctuation confound outcomes [17].

Durability unknown. The longest published follow-up is 6 months. AD is a chronic, lifelong condition — whether MSC infusions provide durable disease modification (months to years) or require repeated dosing is unknown. The Th2/Treg rebalancing mechanism suggests the potential for longer remissions than biologics, but this remains theoretical.

Optimal protocol undefined. Key parameters — MSC source (umbilical cord vs. bone marrow vs. adipose), dose (1–5 × 10⁶ cells/kg), route (IV alone vs. IV + topical), and frequency (single infusion vs. monthly × 3 vs. maintenance dosing) — all remain unstandardized. Different protocols appear in different studies, making cross-study comparison nearly impossible [18].

Cost and access. MSC therapy is not covered by insurance for AD and is expensive (typically $5,000–15,000 USD per treatment course). It is currently available only at specialized regenerative medicine centers, limiting access and creating potential equity concerns.

Safety monitoring. While MSCs have a favorable short-term safety profile (no tumorigenicity signals, no pulmonary embolism with proper infusion technique), long-term safety data in the AD population — particularly in patients with concomitant atopic comorbidities and Th2-dominant immune profiles — is minimal. Theoretical risks include paradoxical immune activation and pro-fibrotic effects in susceptible individuals [19].

Frequently Asked Questions

How does MSC therapy work for eczema differently than steroid creams?

Steroid creams suppress inflammation locally at the skin surface by inhibiting phospholipase A2 and reducing prostaglandin/leukotriene production. They do not address the systemic Th2-skewed immune dysregulation that sustains the disease. MSCs work systemically — they are infused intravenously, migrate to sites of inflammation, and secrete a broad array of immunomodulatory factors that rebalance the Th2/Treg axis, stabilize mast cells, and promote barrier repair. In principle, MSC therapy targets the root immunological dysfunction rather than the downstream symptom.

How much does stem cell therapy for eczema cost in Thailand?

At VELAR Center in Bangkok, an MSC treatment course for atopic dermatitis typically ranges from 300,000–600,000 THB (approximately $8,500–$17,000 USD), depending on cell dose, number of infusions, and protocol complexity. This includes pre-treatment immunological profiling, the cell product, infusion monitoring, and follow-up assessments. A detailed quote is provided after the initial consultation and biomarker evaluation.

Is MSC therapy safe for children with atopic dermatitis?

Limited pediatric data exist — a small 2022 study of eight children aged 3–12 reported no serious adverse events with umbilical cord MSC infusions, but the evidence base is too small for definitive safety conclusions. MSC therapy for pediatric AD should be considered only in the context of severe, treatment-resistant disease after exhaustive discussion of risks, benefits, and the investigational nature of the intervention.

How many treatments are needed, and how long do results last?

Published protocols have used 1–3 intravenous infusions spaced 4 weeks apart. The longest published follow-up is 6 months, with many patients maintaining EASI-50 or better at that time point. Whether results extend to 12–24 months or longer — and whether maintenance infusions are required — is not yet known. Durability is arguably the most important unanswered question in MSC research for AD.

Can MSC therapy cure eczema permanently?

No. There is no evidence that MSC therapy "cures" atopic dermatitis. AD is a complex, polygenic condition involving barrier protein mutations (FLG), lifelong atopic predisposition, and environmental triggers. MSCs may induce prolonged remission by resetting immune imbalance, but the underlying genetic susceptibility remains. Some patients may require periodic booster infusions; others may see benefits wane as the immune system gradually returns to its baseline atopic phenotype.

What makes someone a good candidate for MSC therapy for eczema?

Ideal candidates are adults with moderate-to-severe AD (EASI ≥ 16) who have failed or cannot tolerate at least two systemic therapies (e.g., dupilumab, cyclosporine, methotrexate, or JAK inhibitors) and who have elevated serum IgE and Th2-biased inflammatory markers. Contraindications include active systemic infection, known malignancy, pregnancy, and severe hepatic or renal impairment. Every candidate requires a comprehensive immunological and medical evaluation before proceeding.

The VELAR Approach

At the VELAR Center in Bangkok, the approach to atopic dermatitis begins with immunophenotyping — measuring serum IgE, eosinophil count, TARC/CCL17, LDH, and cytokine profiles (IL-4, IL-5, IL-13, IL-31) — to characterize each patient's specific inflammatory signature. Treatment uses Wharton's jelly-derived MSCs manufactured under cGMP standards, with dosing individualized based on body weight, disease severity, and biomarker profile. Intravenous infusion is the primary route, supported by pre-infusion antihistamine and corticosteroid premedication to minimize infusion reactions. Regular follow-up with repeat EASI scoring, pruritus VAS, DLQI, and serum biomarker monitoring at 1, 3, 6, and 12 months provides objective outcome data [20].

Important: MSC therapy for atopic dermatitis is investigational. Results vary between patients. This article summarizes published preclinical and clinical research and the clinical reasoning behind the MSC approach — it does not constitute a treatment guarantee or medical advice. All treatment decisions should be made in consultation with a qualified physician after a thorough individual assessment.

References

  1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. doi:10.1016/S0140-6736(20)31286-1 ↩
  2. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21-40. doi:10.1038/s41573-021-00266-6 ↩
  3. Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76. doi:10.1016/j.jaci.2017.01.011 ↩
  4. Shin TH, Kim HS, Choi SW, Kang KS. Mesenchymal stem cell therapy for inflammatory skin diseases: clinical potential and mode of action. Int J Mol Sci. 2017;18(2):244. doi:10.3390/ijms18020244 ↩
  5. Kim HJ, Park JS. Usage of human mesenchymal stem cells in cell-based therapy: advantages and challenges. Dev Reprod. 2017;21(1):1-10. doi:10.12717/DR.2017.21.1.001 ↩
  6. Na K, Yoo HS, Zhang YX, et al. Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis. Cell Death Dis. 2014;5:e1345. doi:10.1038/cddis.2014.299 ↩
  7. Sah SK, Agrahari G, Nguyen CT, et al. Enhanced therapeutic effects of human mesenchymal stem cells transduced with superoxide dismutase 3 in a murine atopic dermatitis-like skin inflammation model. Allergy. 2018;73(12):2364-2376. doi:10.1111/all.13596 ↩
  8. Brown JM, Nemeth K, Kushnir-Sukhov NM, Metcalfe DD, Mezey E. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy. 2011;41(4):526-534. doi:10.1111/j.1365-2222.2010.03685.x ↩
  9. Wu P, Zhang B, Shi H, Qian H, Xu W. MSC-exosome: a novel cell-free therapy for cutaneous regeneration. Cytotherapy. 2018;20(3):291-301. doi:10.1016/j.jcyt.2017.11.002 ↩
  10. Shin TH, Lee BC, Choi SW, et al. Human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation. Oncotarget. 2017;8(1):512-522. doi:10.18632/oncotarget.13473 ↩
  11. Kim HS, Yun JW, Shin TH, et al. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-β1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells. 2015;33(4):1254-1266. doi:10.1002/stem.1913 ↩
  12. Cho BS, Kim JO, Ha DH, Yi YW. Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis. Stem Cell Res Ther. 2018;9(1):187. doi:10.1186/s13287-018-0939-5 ↩
  13. Kim JY, Park S, Lee JH, et al. Case report: mesenchymal stem cell therapy for refractory atopic dermatitis. Front Immunol. 2021;12:678954. doi:10.3389/fimmu.2021.678954 ↩
  14. Park YB, Lee S, Kim J, et al. Allogeneic umbilical cord blood-derived mesenchymal stem cell treatment for moderate-to-severe atopic dermatitis: a phase 1/2a clinical trial. Stem Cells Transl Med. 2022;11(5):478-488. doi:10.1093/stcltm/szac013 ↩
  15. Wang L, Zhang Y, Li H, et al. Umbilical cord mesenchymal stem cell therapy for pediatric atopic dermatitis. World J Pediatr. 2022;18(12):812-819. doi:10.1007/s12519-022-00615-6 ↩
  16. Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis: the path to targeted therapy. J Allergy Clin Immunol. 2019;143(5):1611-1624. doi:10.1016/j.jaci.2018.11.031 ↩
  17. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z ↩
  18. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  19. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  20. Kim JH, Lee SH, Seo KW, et al. Clinical outcomes of Wharton's jelly-derived mesenchymal stem cell therapy for atopic dermatitis: a prospective case series. J Clin Med. 2023;12(3):1021. doi:10.3390/jcm12031021 ↩